Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
06:53
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

WFH 2016 World Congress

 

24-28 July 2016 Orlando
FAQs
   
Discussion forum - WFH 2016 World Congress
    Topic - Inhibitors

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Bleeding characteristics of patients with congenital hemophilia and inhibitors: data from a postmarketing study of recombinant activated factor VII (SMART-7)  CAROLINE COOK 1      7/19/2016 1:20:00 PM  
Final results of the Prospective Advate ITI Registry (PAIR) Immune Tolerance Induction (ITI) experience with Advate  Jimena Goldstine 1      7/18/2016 5:57:00 PM  
Low-titer inhibitors in children with severe hemophilia A: real-life data from the REMAIN study.  Maria Elisa 1      7/14/2016 8:00:00 AM  
REal life MAnagement of children with severe hemophilia A and INhibitors: first results of the REMAIN study.  Maria Elisa 1      7/14/2016 7:58:00 AM  
Anti- factor VIII IgG4 and intracellular cytokines profile in T and B cells from hemophilia A patients with complete success, failure, or relapse after immune tolerance induction treatment: longitudinal evaluation with five years follow-up  Silmara Aparecida Lima 1      7/7/2016 9:28:00 PM  
South Mimms Inhibitor Assay (SMIA): an affordable and improved method for measurement of FVIII inhibitors  Sanj Raut 1      7/7/2016 8:51:00 PM  
Immune Tolerance Induction in Hemophilia A a Single Center Experience  Maria Coutinho 1      7/7/2016 7:21:00 PM  
Status of inhibitor hemophilia patients in different age groups  Nadezhda Zozulya 1      7/7/2016 5:19:00 PM  
Preliminary in vitro results from the PredicTGA study: thrombin generation assay (TGA) as a test of haemostatic effectiveness of factor VIII concentrates in patients with Hemophilia A and inhibitors  Armando Tripodi 1      7/7/2016 4:06:00 PM  
Thrombin generation assay (TGA) for testing haemostatic response in patients with Hemophilia A and inhibitors on immune tolerance induction treatment (ITI): preliminary in vivo results from the PredicTGA study  Armando Tripodi 1      7/7/2016 4:03:00 PM  
Prevalence of Inhibitors in Hemophilia - A single centre study.  Parismrita Borah 1      7/7/2016 3:00:00 PM  
Prophylactic treatment and Rituximab subsequent immune tolerance induction therapy to improve inhibitor eradication on resistant ITI in severe hemophilia A patients with inhibitor  Shin-Nan Cheng 1      7/7/2016 8:09:00 AM  
Risk factors associated with High-titre Inhibitors development in Previously Untreated Hemophilia A patients (PUPS-HA) born between 2000 and 2013: A single center experience  Arlette Ruiz-Sáez 1      7/7/2016 4:30:00 AM  
Inhibitor risks in Argentine patients with severe HA. F8 genotype, status concordance in sibling pairs and immune gene polymorphisms studies  Claudia Pamela 1      7/6/2016 8:52:00 PM  
Development and evaluation of a novel FVIII domain-specific multiplex microsphere based immunoassay for characterization of anti-FVIII antibodies  Behnaz Pezeshkpoor 1      7/6/2016 5:13:00 PM  
Prophylaxis with FEIBA three days a week results in safe and effective hemostasis in children with Hemophilia A with inhibitors  Mark Belletrutti 1      7/6/2016 6:41:00 AM  
Primary prophylaxis and inhibitor development in patients with severe Hemophilia A and B  Marilia Renni 1      7/6/2016 3:39:00 AM  
Long-term course of inhibitors against factor VIII concentrates in hemophilia A patients  KIYOUNG YOO 1      7/4/2016 3:03:00 AM  
Combined FEIBA- FVIII therapy a potential treatment for patients with hemophilia and inhibitors- a thrombin generation based study  tami livnat 1      7/3/2016 10:30:00 AM  
Inhibitor incidence in a cohort of South African people with severe hemophilia A is not higher than for Caucasian patients.  Johnny Mahlangu 1      7/1/2016 6:04:00 PM  
Analytical performance of the Nijmegen assay using different buffered reagents.  Yuen On Wan 1      6/27/2016 4:33:00 PM  
Impact of FVIII source in the Bethesda-Nijmegen inhibitor test result. Difference between FVIII/VWF complex concentrates and concentrates of isolated FVIII  Ana María Ortiz 1      6/22/2016 11:51:00 AM  
Sequential combined bypassing therapy for refractory bleeding in two adolescent hemophiliacs with inhibitors  ZHRE KAYA 1      6/17/2016 10:00:00 AM  
Haemophilia A with inhibitor in children: Experience of a single center in the last 25 years  Zafer Salcioglu 1      6/16/2016 2:00:00 PM  
Variable Success with Immune Suppressive Therapy in Rescuing Immune Tolerance Induction in Children with Severe Haemophilia A, FVIII inhibitors and unfavorable prognostic factors  Viacheslav Dmitriev 1      6/9/2016 4:15:00 PM  
       




Most viewed poster for this congress
Poster: 13
Visits: 590
Title: Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders
Authors: Jay Bryant-Wimp , Jay Bryant-Wimp, RPh
Centre: Integrite Solutions

Poster most viewed in this topic
Poster: 66
Visits: 94
Title: Inhibitor risks in Argentine patients with severe HA. F8 genotype, status concordance in sibling pairs and immune gene polymorphisms studies
Authors: Claudia Pamela , Claudia Pamela Radic
Centre: IMEX-CONICET/ANM


 






PosterSessionOnline
Logo Draft
 
Logo Cert